SymBio Pharmaceuticals Company Description
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and sales of pharmaceuticals and related operations to treat cancer, hematology, and viral infectious diseases in Japan and internationally.
It offers SyB L-0501, an anti-cancer agent for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administration under the TREAKISYM name.
The company also engages in the development of SyB L-1101, an intravenous formulation, which completed Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II clinical trial in combination with AZA to treat HR-MDS.
In addition, it is involved in the development SyB V-1901, an antiviral drug. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
| Country | Japan |
| Founded | 2005 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Fuminori Yoshida |
Contact Details
Address: Toranomon 30 Mori Building Tokyo, 105-0001 Japan | |
| Phone | 81 3 5472 1125 |
| Website | symbiopharma.com |
Stock Details
| Ticker Symbol | SYMQY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | US87150Y1001 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fuminori Yoshida | Chief Executive Officer, President and Representative Director |
| Takaaki Fukushima | Managing Executive Officer and Chief Financial Officer |
| Koji Fukushima | Executive Officer and Deputy CMO |
| Yoshiharu Torikai | Corporate Officer |
| Masahiko Okuno | Corporate Officer |
| Hiroyuki Horita | Corporate Officer |